Drug Trial Radar · NCT07365241
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
531
Planned (sponsor's estimate)
Start
Jul 2, 2026
Primary completion
Sep 2030
Study completion Sep 2030
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jan 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, tolerability, and change in disease activity of ABBV-706 compared to standard of care (SOC) treatment (topotecan, lurbinectedin, or amrubicin). ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are two treatment arms in this study. Participants will either receive ABBV-706 or SOC. Approximately 531 adult participants will be enrolled in the study across 175 sites worldwide. Participants with SCLC will receive intravenous (IV) ABBV-706 or SOC \[topotecan (IV or orally), or lubinectedin (IV), or amrubicin (IV)\]. The estimated duration of the study is approximately 53 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.
Conditions
- Small Cell Lung Cancer
Interventions
ABBV-706Drug
Intravenous (IV) Infusion
TopotecanDrug
IV Infusion
TopotecanDrug
Oral
LurbinectedinDrug
IV Infusion
AmrubicinDrug
IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response (OR) as Measured by Overall Response Rate (ORR) Based on Blinded Independent Central Review (BICR)Time frame: Up to approximately 24 months
- Overall Survival (OS)Time frame: Up to approximately 28 months
Locations
72 sites in 10 countries. Site status is shown where the registry gives one.
Birmingham Hematology and Oncology Associates d/b/a Alabama Oncology /ID# 280063
Birmingham, Alabama · Recruiting
Usa Mitchell Cancer Institute /ID# 280198
Mobile, Alabama · Recruiting
City Of Hope - Phoenix /ID# 281323
Goodyear, Arizona · Recruiting
City of Hope National Medical Center /ID# 281322
Duarte, California · Recruiting
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 281396
Irvine, California · Recruiting
Florida Cancer Specialists & Research Institute - South /ID# 281387
Fort Myers, Florida · Recruiting
Orlando Health Cancer Institute /ID# 280418
Orlando, Florida · Recruiting
Moffitt Cancer Center /ID# 279732
Tampa, Florida · Recruiting
City Of Hope - Atlanta /ID# 279929
Newnan, Georgia · Recruiting
University of Chicago Medical Center /ID# 280149
Chicago, Illinois · Recruiting
OSF St. Francis Medical Center /ID# 279930
Peoria, Illinois · Recruiting
Springfield Clinic - First /ID# 281309
Springfield, Illinois · Recruiting
City Of Hope - Chicago /ID# 281335
Zion, Illinois · Recruiting
Franciscan St. Francis Health /ID# 279788
Indianapolis, Indiana · Recruiting
Baptist Health Louisville /ID# 280025
Louisville, Kentucky · Recruiting
Dana-Farber Cancer Institute /ID# 279690
Boston, Massachusetts · Recruiting
Cancer And Hematology Centers Of Western Michigan - Grand Rapids /ID# 279955
Grand Rapids, Michigan · Recruiting
Minnesota Oncology - Edina Clinic /ID# 280698
Edina, Minnesota · Recruiting
Mayo Clinic Hospital Rochester /ID# 279784
Rochester, Minnesota · Recruiting
Inspira Medical Center Mullica Hill /ID# 280574
Mullica Hill, New Jersey · Recruiting
FirstHealth of the Carolinas- Speciality Center /ID# 279857
Pinehurst, North Carolina · Recruiting
Oncology Hematology Care - Fairfield /ID# 280641
Fairfield, Ohio · Recruiting
Willamette Valley Cancer Institute and Research Center /ID# 280617
Eugene, Oregon · Recruiting
Oregon Health and Science University /ID# 280071
Portland, Oregon · Recruiting
St. Lukes University Hospital /ID# 280204
Bethlehem, Pennsylvania · Recruiting
Tennessee Cancer Specialists - Knoxville - Old Weisgarber Road /ID# 280619
Knoxville, Tennessee · Recruiting
University Of Tennessee Medical Center /ID# 279896
Knoxville, Tennessee · Recruiting
Baptist Memorial Hospital /ID# 281405
Memphis, Tennessee · Recruiting
SCRI Oncology Partners /ID# 279779
Nashville, Tennessee · Recruiting
Vanderbilt University Medical Center /ID# 280169
Nashville, Tennessee · Recruiting
The University of Texas MD Anderson Cancer Center /ID# 280070
Houston, Texas · Recruiting
Texas Oncology - Northeast Texas /ID# 280642
Tyler, Texas · Recruiting
Blue Ridge Cancer Care - Blacksburg /ID# 281583
Blacksburg, Virginia · Recruiting
Virginia Cancer Specialists - Fairfax /ID# 280710
Fairfax, Virginia · Recruiting
Shenandoah Oncology /ID# 280699
Winchester, Virginia · Recruiting
West Virginia University Hospitals /ID# 279883
Morgantown, West Virginia · Recruiting
University of Wisconsin /ID# 279909
Madison, Wisconsin · Recruiting
Universitaetsklinikum Krems /ID# 280608
Krems, Lower Austria, Austria · Recruiting
Ordensklinikum Linz Elisabethinen /ID# 281314
Linz, Upper Austria, Austria · Recruiting
AZ-Delta. /ID# 280341
Roeselare, West-Vlaanderen, Belgium · Recruiting
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.